Free Preview — Investor scores & financials for ILMN. Sign up for full buy targets.
Start Free
IL

Illumina, Inc.

ILMN

Healthcare · Medical - Diagnostics & Research · NASDAQ

$203.01

P/E 37.5×

CEO

Jacob Thaysen

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.

Investor model analysis

Details locked

Intrinsic Value (DCF)

Warren Buffett's valuation model · select an investor above to switch

Intrinsic Value

████

Buy Below

████

Strong Buy

████

Margin of Safety

████

Unlock buy targets with a free account

Get started

Create a free account to see buy targets, full checklists & risk analysis Get started

Scenario analysis

Bear, base & bull

Three growth assumptions, three fair values — and where today's price lands

What's working

Key strengths

Identified by Buffett framework analysis

Return on Equity

ROE Quality (Low Leverage)

Debt Levels

Risk factors & concerns — free account

Unlock

Company financials

5-Year Financials

Income statement highlights — annual, USD

Metric20252024202320222021
Revenue$4.3B
$4.4B
$4.5B
$4.6B
$4.5B
Rev. Growth+0.8%+3.0%+1.8%-1.3%
Net Income$850M-$1.2B-$1.2B-$4.4B$762M
Net Margin19.6%-28.0%-25.8%-96.1%16.8%
EPS (Diluted)$5.48$-7.69$-7.35$-28.05$5.08
Free Cash Flow████████████████████

Full analysis included

See the complete picture for ILMN

Exact buy targets, margin of safety, detailed investor checklists, and risk breakdown — all frameworks, all numbers.

Buy & sell targetsFull checklistRisk breakdown

Free: 3 analyses/month · Pay per stock: $4.99 · Pro: $19.99/mo

Educational Use Only · Not Financial Advice

Analysis, scores, valuations, and buy zones are derived from publicly documented investor frameworks (Buffett, Lynch, Benjamin Graham, Phil Town) for learning purposes only. They are not recommendations from licensed financial advisors. Past performance does not guarantee future results. Prices may be delayed up to 15 minutes. Always conduct your own research before making any investment decisions.